|Bid||2.1000 x 1400|
|Ask||2.1600 x 3000|
|Day's Range||2.1300 - 2.2000|
|52 Week Range||2.0100 - 11.5500|
|Beta (5Y Monthly)||3.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2020 - Mar 9, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Celldex Therapeutics, Inc. (CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells.
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HAMPTON, N.J., Nov. 12, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019..
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s preclinical pipeline this weekend. A review of the CDX-0159 early development program was presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting on November 9, 2019 in the Distinguished Industry Oral Abstract Session. Preclinical data supporting the continued development of the Company’s CDX-527 bispecific candidate were also presented at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting (SITC 2019), including both a poster presentation on November 9, 2019 and a talk during the preconference program session “Novel Multi-Targeted Therapeutic Platforms” on Wednesday, November 6, 2019.
Celldex Therapeutics, Inc. (CLDX) presented data from the Company’s ongoing CD40 agonist program today at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting. CD40, expressed on dendritic cells and other antigen presenting cells, is an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex Therapeutics, Inc. (CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. CDX-1140: The abstract (Abstract ID: P827) entitled, “Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers” will be presented in a poster presentation by Rachel Sanborn, MD, Co-director of the Thoracic Oncology Program and Leader of the Phase 1 Trials Program at Providence Cancer Institute and a lead investigator in this study, on Friday, November 8, 2019 from 8:00 am to 8:00 pm ET. Michael Yellin, MD, Vice President of Clinical Science at Celldex will also present a talk entitled CD40: A Target for Systemic Immune Modulation at the Workshop on Intratumoral Immunomodulation on Thursday, November 7, 2019 at 3:00 pm ET.
HAMPTON, N.J., Sept. 30, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor.
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
The clinical-stage biotech continued to conserve cash while conducting multiple clinical studies in the second quarter.
Celldex (CLDX) delivered earnings and revenue surprises of 28.21% and -43.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics, Inc. (CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter 2019 financial results and to provide an update on key research and development and business objectives for the remainder of 2019. The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com.
Celldex Therapeutics, Inc. (CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019. "Dr. Young’s notable career and strong track record of successful drug development make her an important addition to Celldex," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics.
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
Celldex Therapeutics, Inc. (CLDX) today presented results from the CDX-3379 clinical program at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. To date, three studies of CDX-3379 have enrolled patients with head and neck squamous cell carcinoma (HNSCC), including the ongoing Phase 2 exploratory study of CDX-3379 in combination with Erbitux® (cetuximab) in patients with cetuximab-resistant, advanced human papillomavirus (HPV) negative HNSCC who have previously been treated with an anti-PD1 checkpoint inhibitor. Emerging data from the Phase 2 study and earlier studies of CDX-3379 suggest that antitumor activity may be associated with somatic mutations in certain genes.